
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
AAD show essentials Staying one step ahead of the hustle and bustle of the American Academyof Dermatology annual meeting is a big easy when you know the basics.